Germany’s DRG Reform Must Retain Incentives For Medtech Innovation, Says Industry

New system must be able to pay for the best technologies

German health ministry plans to change how inpatient care is paid for and increase levels of ambulatory care have ignited a debate among industry and other stakeholders. The medtech industry gave its initial reaction to Medtech Insight.

Shutterstock

The biggest change in two decades in how health care is paid for in Germany has been proposed by the health ministry (BMG), amid concerns that the current method of reimbursement for inpatient services has produced a costly system that is prone to over-treatment.

More from Germany

German Medtechs Up The Stakes On Amending Hospital Reform Law

 
• By 

Whoever is handed the health portfolio in Germany’s new coalition government will face demands to amend the recently-enacted hospital and DRGs reform law. The medtech industry has been quick to make the case for change.

New German Coalition Expected To Prioritize Prevention And Healthcare Deregulation

 
• By 

Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.

A Blueprint For The Future: Germany’s Medtech Sees Chance In More Government Roundtables

 
• By 

Germany’s government-industry healthcare industry roundtables have yielded a final report, even though the program was curtailed by the snap election. The new CDU-led government should pick up the baton, medtech industry associations say.

New German Government Told To Keep Medtech Outside Tariffs Bargaining

 
• By 

Germany’s center-right Union won the right on 23 February to head the governing coalition for the next four years, but the medtech industry’s first strong message is to ensure exports channels are not impeded by the imposition of US tariffs.

More from Europe

European Medicine Agency’s CHMP Qualifies First AI Tool For Use In Clinical Trials

 

With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Urgent Call for Leadership In EU Medtech To Steer Through Regulatory Challenges

 

EU medtech trade associations present detailed arguments for the European Commission’s 'targeted evaluation' of medtech regulations, highlighting the need for immediate course correction.